Healthcare / BiotechnologyNasdaqGM
$3.72
-0.23 (-5.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-171.1M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$265M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-63.4%
↓Gross Margin
N/A
•Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-137.1M · FCF $-125.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | — | — | $67.4M | — | — | — | — | — |
| Net Income | $-137.1M | $-137.1M | $-165.8M | $-292.2M | $-236.8M | $-158.7M | $-117.8M | $-45.7M |
| EBITDA | $-144.3M | $-144.3M | $-186.2M | $-252.6M | $-225.9M | $-216.0M | $-118.6M | $-46.7M |
| EPS | — | — | -2.33 | -4.47 | -4.48 | -3.72 | -4.19 | -8.16 |
| Operating Margin | — | — | -278.0% | — | — | — | — | — |
| Net Margin | — | — | -246.0% | — | — | — | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.17 | 0.17 | 0.12 | 0.10 | 0.10 | — | — | — |
| Current Ratio | 6.19 | 6.19 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-125.2M | $-125.2M | $-171.1M | $-208.4M | $-166.3M | $-160.2M | $-87.6M | $-39.5M |
| Returns | ||||||||
| ROE | -63.4% | -63.4% | -49.2% | -66.8% | -54.6% | — | — | — |
| Valuation | ||||||||
| P/B | 1.19 | 1.19 | 0.68 | 2.30 | 2.58 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | — | — | 47.9% | 0.2% | — | 11.2% | 48.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+173.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.33 → n/d
Residual
+173.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.